Discoveries and Innovations
- Helped develop lifesaving procedures including angioplasty and drug-eluting stents, and newer technologies such as off-pump surgery.
- Created lamivudine (3TC) and emtricitabine (FTC), two of the most commonly used and most successful HIV/AIDS drugs, taken by more than 94% of U.S. patients on therapy and by thousands more around the world
- Developed one of the leading vaccine candidates against HIV, already tested in preclinical and early stage clinical trials and currently in phase II trials
- Developed brain mapping to guide effective surgical approaches (deep brain stimulation) to treat movement disorders such as Parkinson's and dystonia
- Discovered the gene responsible for fragile X syndrome, the most common cause of inherited intellectual disability, and now working to develop drug therapy to treat it.
- Helped develop belatacept, a post-transplant drug that is less toxic and more effective than current immunosuppressants.
- Discovered the role of PD-1 (programmed cell death 1) in inhibiting the T cell immune response to chronic viral infections.
- Discovered in the laboratory, then in early-stage clinical trials, the beneficial effects of progesterone to treat traumatic brain injury, the first new treatment for TBI in 30 years. Currently leading a large nationwide NIH-supported clinical trial of progesterone and TBI.
- Developing an effective method of using deep-brain stimulation as therapy for treatment-resistant severe depression.
- Winship Cancer Institute of Emory University is the only National Cancer Institute-designated cancer center in Georgia.
- The Yerkes National Primate Research Center of Emory University is one of only eight NIH-designated national primate research centers in the country.
- Emory is one of eight NIH-sponsored Vaccine Evaluation and Treatment Units (VTEUs) conducting clinical trials for vaccines for infectious diseases, including H1N1 flu.
- Emory is a leader in technology transfer, with more than 50 products in various stages of development of regulatory approval – 27 products having reached the marketplace and 12 more in human clinical trials. Over the past two decades, the WHSC has helped Emory launch 57 start-up companies and bring more than $806 million into Georgia in licensing revenues from drugs, diagnostics, devices, and consumer products.
- The research partnership between Emory and Georgia Tech includes the No. 2-ranked (U.S. News & World Report) Wallace H. Coulter Department of Biomedical Engineering, the Georgia Tech-Emory Center for Regenerative Medicine (GTEC), the Emory/Georgia Tech Predictive Health Institute, and one of the nation's largest NIH-funded research programs in nanomedicine.
External Research Funding
- Emory University total external research funding, FY12: $520.3 million
- Woodruff Health Sciences Center external research funding, FY12: $483.4 million
- Emory University funding by federal agencies, FY12: $349 million
- Emory University NIH funding, FY12: $299 million